JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Recruiting · NCT07336823 · Registry updated 2026-01-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2026-01-13 | NCT07336823 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhen Genocury Biotech Co., Ltd. | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Foshan First People's Hospital | Foshan | China | 6 |